Karl Anderson, MD

Projects

Projects per year 1900 1900 2013 2016 2018 2026

• 11 Active
• 49 Completed

Projects per year

Search results

• Active

  A Phase 3, Multicenter, Open-Label, Long-Term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

  Anderson, K.

  10/25/21 → 10/24/26

  Project: Other project

• Alnylam Pharmaceuticals, Inc. - 0306060, Assessing Patients' Experiences With Acute Hepatic Porphyria: Exit Interviews (Pro00053618)

  Anderson, K.

  10/6/21 → 10/5/24

  Project: Other project

• Alnylam Pharmaceuticals, Inc. - 0306060, Assessing Patients' Experiences With Acute Hepatic Porphyria: Exit Interviews (Pro00053618)

  Anderson, K.

  Alnylam Pharmaceuticals, Inc

  10/6/21 → 10/5/24

  Project: Other project

• ELEVATE, a global observational longitudinal prospective registry of patients with acute hepatic porphyria (AHP)

  Anderson, K.

  8/20/21 → 8/19/26

  Project: Other project

• RE- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X Linked Protoporphyria

  Anderson, K.

  5/15/21 → 9/16/25

  Project: Other project

• RE: Porphyria Rare Disease Clinical Research Consortium (RDCRC)

  Anderson, K.

  5/14/21 → 6/30/23

  Project: Other project

• A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X Linked Protoporphyria

  Anderson, K.

  Mitsubishi Tanabe Pharma

  9/17/20 → 9/16/25

  Project: Other project

• A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X Linked Protoporphyria

  Anderson, K.

  Mitsubishi Tanabe Pharma

  9/17/20 → 9/16/25

  Project: Other project

• A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Erythropoietic Protoporphyria

  Anderson, K.

  6/6/18 → 6/5/23

  Project: Other project

• A Natural History Study of Acute Hepatic Porphyria (AHP) Patients with Recurrent Attacks ALN-AS1-NT-001

  Anderson, K.

  Alnylam Pharmaceuticals, Inc

  8/14/14 → 12/31/23

  Project: Other project

• A Natural History Study of Acute Hepatic Porphyria (AHP) Patients with Recurrent Attacks ALN-AS1-NT-001

  Anderson, K.

  8/14/14 → 12/31/23

  Project: Other project

• Completed

  A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X Linked Protoporphyria

  Anderson, K.

  9/17/20 → 5/14/21

  Project: Other project

• Porphyria Rare Disease Clinical Research Consortium (RDCRC)

  Anderson, K.

  Icahn School of Medicine at Mount Sinai

  9/18/19 → 6/30/21

  Project: Other project

• Porphyria Rare Disease Clinical Research Consortium (RDCRC)

  Anderson, K.

  Icahn School of Medicine at Mount Sinai

  9/18/19 → 6/30/21

  Project: Other project

• Porphyria Rare Disease Clinical Research Consortium (RDCRC)

  Anderson, K.

  9/18/19 → 5/14/21

  Project: Other project

• Task Order 1

  Anderson, K.

  7/17/18 → 12/31/19

  Project: Other project

• Task Order 1

  Anderson, K.

  Aptinyx Inc

  7/17/18 → 12/31/19

  Project: Other project

• Testing Services

  Anderson, K.

  7/17/18 → 12/31/19

  Project: Other project

• A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Erythropoietic Protoporphyria

  Anderson, K.

  Mitsubishi Tanabe Pharma

  6/6/18 → 11/30/20

  Project: Other project

• A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Erythropoietic Protoporphyria

  Anderson, K.

  6/6/18 → 11/30/20

  Project: Other project

• ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyrias

  Anderson, K.

  3/8/18 → 3/31/21

  Project: Other project

• ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyrias

  Anderson, K.

  Alnylam Pharmaceuticals, Inc

  3/8/18 → 9/4/21

  Project: Other project

• ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyrias

  Anderson, K.

  3/8/18 → 9/4/21

  Project: Other project

• Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects with Chronic Hepatitis C

  Anderson, K.

  6/22/17 → 4/30/22

  Project: Other project

• Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects with Chronic Hepatitis C

  Anderson, K.

  6/22/17 → 5/14/21

  Project: Other project

• Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects with Chronic Hepatitis C

  Anderson, K.

  Wake Forest University

  6/22/17 → 4/30/22

  Project: Other project

• A Multicenter, Open-label Extension Study to Evaluate the long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients with Acute Intermittent Porphyria who have Completed a previous Clinical Study with ALS-AS1

  Anderson, K.

  12/28/16 → 4/30/21

  Project: Other project

• A Multicenter, Open-label Extension Study to Evaluate the long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients with Acute Intermittent Porphyria who have Completed a previous Clinical Study with ALS-AS1

  Anderson, K.

  Alnylam Pharmaceuticals, Inc

  12/28/16 → 4/30/21

  Project: Other project

• A Multicenter, Open-label Extension Study to Evaluate the long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients with Acute Intermittent Porphyria who have Completed a previous Clinical Study with ALS-AS1

  Anderson, K.

  12/28/16 → 4/30/21

  Project: Other project

• RE:A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria

  Anderson, K.

  11/12/16 → 8/31/21

  Project: Other project

• RE:A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria

  Anderson, K.

  11/12/16 → 8/31/21

  Project: Other project

• A PHASE 1, SINGLE-ASCENDING DOSE, MULTIPLE-ASCENDING DOSE, AND MULTI DOSE SAFETY, TOLERABILITY, PHARAMCOKINETICS, AND PHARACODYNAMICS STUDY OF SUBCUTANEOUSLY ADMINISTERED ALN-AS1 IN PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP)

  Anderson, K.

  Alnylam Pharmaceuticals, Inc

  1/22/16 → 1/21/19

  Project: Other project

• A PHASE 1, SINGLE-ASCENDING DOSE, MULTIPLE-ASCENDING DOSE, AND MULTI DOSE SAFETY, TOLERABILITY, PHARAMCOKINETICS, AND PHARACODYNAMICS STUDY OF SUBCUTANEOUSLY ADMINISTERED ALN-AS1 IN PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP)

  Anderson, K.

  1/22/16 → 1/21/19

  Project: Other project

• A PHASE 1, SINGLE-ASCENDING DOSE, MULTIPLE-ASCENDING DOSE, AND MULTI DOSE SAFETY, TOLERABILITY, PHARAMCOKINETICS, AND PHARACODYNAMICS STUDY OF SUBCUTANEOUSLY ADMINISTERED ALN-AS1 IN PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP)

  Anderson, K.

  1/22/16 → 1/21/19

  Project: Other project

• Porphyria Rare Disease Clinical Research Consortium (PDCRC)

  Anderson, K.

  9/27/14 → 8/31/19

  Project: Other project

• A Natural History Study of Acute Hepatic Porphyria (AHP) Patients with Recurrent Attacks ALN-AS1-NT-001

  Anderson, K.

  8/14/14 → 2/10/21

  Project: Other project

• A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria

  Anderson, K.

  11/12/13 → 8/31/20

  Project: Other project

• A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria

  Anderson, K.

  Recordati Rare Diseases Inc

  11/12/13 → 8/31/21

  Project: Other project

• A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria

  Anderson, K.

  11/12/13 → 8/31/21

  Project: Other project

• A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria

  Anderson, K.

  Recordati Rare Diseases Inc

  11/12/13 → 8/31/21

  Project: Other project

• Phase 2 Study of Hemin for Treatment and Prevention of Porphyria Attacks

  Anderson, K.

  9/16/13 → 8/31/21

  Project: Other project

• Phase 2 Study of Hemin for Treatment and Prevention of Porphyria Attacks

  Anderson, K.

  Food and Drug Administration

  9/16/13 → 8/31/21

  Project: Other project

• Phase 2 Study of Hemin for Treatment and Prevention of Porphyria Attacks

  Anderson, K.

  9/16/13 → 8/31/21

  Project: Other project

• Phase 2 Study of Hemin for Treatment and Prevention of Porphyria Attacks

  Anderson, K.

  9/16/13 → 8/31/21

  Project: Other project

• Effect of Oral Cimetidine in the Protoporphyrias (IND 152831 submitted 9/2/2020)

  Anderson, K.

  1/1/00 → 1/1/00

  Project: Other project

• The ABCG2 transporter in protoporphyrin IX disposition: from toxicity to therapy

  Anderson, K.

  1/1/00 → 1/1/00

  Project: Other project

• Newer Direct-Acting Anti-Viral

  Anderson, K.

  1/1/00 → 1/1/00

  Project: Other project

• RE: A Natural History Study of Acute Hepatic Porphyria (AHP) Patients with Recurrent Attacks ALN-AS1-NT-001

  Anderson, K.

  1/1/00 → 1/1/00

  Project: Other project

• Safety and Efficacy of Panhematin for Prevention of Acute Attacks of Porphyria

  Anderson, K.

  1/1/00 → 1/1/00

  Project: Other project

• Safety and Efficacy of Panhematin for Prevention of Acute Attacks of Porphyria

  Anderson, K.

  1/1/00 → 1/1/00

  Project: Other project